Form 4: Rocket Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold 3,989 shares of common stock on August 16, 2024, to cover tax withholding obligations related to vesting RSUs.
Summary
- On August 16, 2024, Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold 3,989 shares of common stock at a price of $18.504 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
- Following the transaction, Patel directly owns 396,983 shares of Rocket Pharmaceuticals common stock.
- Patel also indirectly owns 5,675 shares through her spouse and 104,927 shares through Adaptive Technology LLC, a limited liability company managed by her husband.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. This sale appears to be related to tax obligations, which is a common reason for such transactions.
Key Dates
| Date | Description |
|---|---|
| 08/16/2024 | Date of stock sale transaction. |
| 08/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.